Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Tysabri Sales Dip But Don’t Swoon After PML Adverse Events

This article was originally published in The Pink Sheet Daily

Executive Summary

Biogen plans to report further progressive multifocal leukoencephalopathy cases only when “they provide substantial new information,” CEO Mullen says.

You may also be interested in...



Debt Clock, Cash Situation Push Elan To Explore Options – Sale, Alliance, Merger?

Firm engages Citgroup to explore strategic options, but some key stakeholders are not encouraged by the news

Debt Clock, Cash Situation Push Elan To Explore Options – Sale, Alliance, Merger?

Firm engages Citgroup to explore strategic options, but some key stakeholders are not encouraged by the news

Biogen, Amylin Feel Impact Of Safety Scares; Another Wrinkle With TOUCH

Biogen Idec's landmark risk management program for Tysabri (natalizumab) is paying another dividend for the company: providing management with a credible source of data to reassure investors nervous about the commercial impact of newly reported cases of progressive multifocal leukoencephalopathy (PML) associated with the MS therapy

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS066914

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel